skip to main content
Experts Database

D. Samba Reddy, PhD, RPh, FAAPS, FAAAS

Professor, Neurosciences and Experimental Therapeutics


College of Medicine


neuroscience, pharmaceutics
pharmaceutics, epilepsy, chemical neurotoxicity, post-traumatic epilepsy
Dr. Samba Reddy

About Dr. Reddy

D. Samba Reddy, PhD, RPh, is a professor of neuroscience and experimental therapeutics at the Texas A&M College of Medicine. He teaches both medical and graduate level courses and directs a research team in central nervous system drug development. Dr. Reddy has made exceptional contributions to the pharmaceutical field through his services during the past 20 years, in addition to serving as an expert member in federal government panels in Washington D.C.

He is a highly trained pharmacist-pharmacologist developing new therapeutics for epilepsy and chemical neurotoxicity. He is developing new drugs for epilepsy and brain disorders, and his research has been continuously funded by the National Institutes for Health (NIH) for over 14 years. He is the principal investigator of an NIH project focusing on novel treatments for organophosphate and chemical nerve agent intoxication, and he directs a Department of Defense project on post-traumatic epilepsy after traumatic brain injury.

Dr. Reddy was elected as fellow of two leading pharmacy organizations - the American Pharmacists Association (APhA) and the American Association of Pharmaceutical Scientists (AAPS). He received the Research Achievement Award in Pharmaceutical Sciences by APhA and Excellence in Research Award by the AAPS. He was named to the Board of Directors for the Global Institute for Hispanic Health and the National Institute for Pharmaceutical Technology and Education and was appointed as chair of the International Commission of the Accreditation Council for Pharmacy Education.

Dr. Reddy received his doctorate in pharmacology from Panjab University in Chandigarh, India. He completed his postdoctoral fellowship with the National Institutes of Health in Bethesda, Maryland.

He serves as expert member and adviser for federal scientific committees, including the NIH, DOD, EPA and USP.

He is the editor-in-chief of International Journal of Pharmaceutical Sciences and Nanotechnology, an editor of Epilepsy Currents and a review editor for Frontiers in Neuroscience and Frontiers in Pharmacology journals. He has published 150 articles, co-authored 250 presentations and delivered 100 lectures worldwide.

Vital Record news coverage

Epigenetic drug therapy offers possible epilepsy prevention

The next major step in treating or even curing epilepsy may come from cancer drugs

February 5, 2018

Researchers crack the neuro-code for treating women with menstrual period-linked epilepsy

A unique platform has been created for clinical trials for catamenial seizures

October 9, 2017

Epigenetic interventions combat complex brain conditions like epilepsy

July 25, 2017